Yi-Tsung Lu
Overview
Explore the profile of Yi-Tsung Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, et al.
Eur Urol Oncol
. 2023 Apr;
6(5):516-524.
PMID: 37087309
Background: Neoadjuvant chemotherapy (NAC) is the standard of care in muscle-invasive bladder cancer (MIBC). However, treatment is intense, and the overall benefit is small, necessitating effective biomarkers to identify patients...
2.
Lu Y, Xu T, Iqbal M, Hsieh T, Luo Z, Liang G, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406487
Chemotherapy resistance is traditionally attributed to DNA mutations that confer a survival advantage under drug selection pressure. However, in bladder cancer and other malignancies, we and others have previously reported...
3.
Xu T, Junge J, Delfarah A, Lu Y, Arnesano C, Iqbal M, et al.
Sci Rep
. 2022 Apr;
12(1):5518.
PMID: 35365706
Genetic mutations have long been recognized as drivers of cancer drug resistance, but recent work has defined additional non-genetic mechanisms of plasticity, wherein cancer cells assume a drug resistant phenotype...
4.
Morrison G, Buckley J, Ostrow D, Varghese B, Cen S, Werbin J, et al.
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269713
Integrating liquid biopsies of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) with other minimally invasive measures may yield more comprehensive disease profiles. We evaluated the feasibility of concurrent cellular...
5.
Xu T, Li H, Wei J, Li M, Hsieh T, Lu Y, et al.
Int J Cancer
. 2020 Feb;
146(11):3065-3076.
PMID: 32017074
Highly tumorigenic, drug-resistant cancer stem-like cells drive cancer progression. These aggressive cells can arise repeatedly from bulk tumor cells independently of mutational events, suggesting an epigenetic mechanism. To test this...
6.
Jan Y, Yoon J, Chen J, Teng P, Yao N, Cheng S, et al.
Theranostics
. 2019 Jun;
9(10):2812-2826.
PMID: 31244925
: Our objective was to develop a circulating tumor cell (CTC)-RNA assay for characterizing clinically relevant RNA signatures for the assessment of androgen receptor signaling inhibitor (ARSI) sensitivity in metastatic...
7.
Lu Y, Delijani K, Mecum A, Goldkorn A
Cancer Manag Res
. 2019 Jun;
11:5271-5291.
PMID: 31239778
In recent years, new therapeutic options have become available for prostate cancer (PC) patients, generating an urgent need for better biomarkers to guide the choice of therapy and monitor treatment...
8.
Hermel D, Nael A, Lu Y, Kim J, Brynes R, Vergara-Lluri M, et al.
Anticancer Drugs
. 2019 Mar;
30(4):416-421.
PMID: 30875349
Gelatinous bone marrow transformation (GBMT) is a rare pathologic entity of unclear etiology characterized by adipose cell atrophy, focal hematopoietic tissue hypoplasia, and a distinct eosinophilic substance that stains with...
9.
Jan Y, Chen J, Zhu Y, Lu Y, Chen S, Chung H, et al.
Adv Drug Deliv Rev
. 2018 Mar;
125:78-93.
PMID: 29551650
Circulating tumor cells (CTCs) are cancer cells shredded from either a primary tumor or a metastatic site and circulate in the blood as the potential cellular origin of metastasis. By...
10.
Cheng S, Chen J, Lu Y, Chung L, Tseng H, Posadas E
Asian J Urol
. 2017 Dec;
3(4):254-259.
PMID: 29264193
One of the major challenges that clinicians face is in the difficulties of accurately monitoring disease progression. Prostate cancer is among these diseases and greatly affects the health of men...